Skip to content


Adept actively engages in biochemical research.  Our primary focus is the development of new small molecule compounds and formulations for the treatment of trauma and the enhancement of human performance, with a particular emphasis on the military and defense markets.  

Our research portfolio encompasses a range of early-stage drug development programs, including a novel augmented tranexamic acid formulation, an orally-active small molecule compound for the treatment of acute burn injuries, and a beta-alanine derivative with a markedly improved pharmacokinetic profile.
For further information about our research initiatives and capabilities, please do not hesitate to contact us directly.  Our team would be happy to address any questions or inquiries you may have.


Tranexamic acid (TXA) is a synthetic lysine derivative that blocks the lysine site on plasminogen and inhibits fibrinolysis. It was first synthesized in 1962, and has seen use in surgical and trauma care applications since. The effects of TXA in trauma care were rigorously studied in the CRASH-2 trial, a randomized, placebo-controlled trial that spanned 274 hospitals in 40 countries.  CRASH-2 sought to assess “the effects of the early administration of a short course of tranexamic acid on death, vascular occlusive events, and the receipt of blood transfusion in trauma patients.” CRASH-2 determined that TXA effectively reduces mortality in hemorrhaging trauma patients. The MATTERS trial subsequently examined TXA’s military relevance in light of CRASH-2.Their findings show “that [post-trauma treatment with] TXA improves markers of coagulation and results in lower mortality. The observation of improved survival confirms findings from the CRASH-2 trial and extends them to a population of patients with wartime injuries.

ADE-1 is a tranexamic acid analog that is complexed with an inositol derivative and additional active agents.  It was developed to exhibit improved antifibrinolytic activity, improved stability in plasma, and a number of additional targeted effects that should ultimately eclipse the survival benefit of tranexamic acid in the seriously injured requiring transfusion.  Unlike TXA, which is primarily used in the treatment of clotting disorders, ADE-1 is being developed specifically for use in military and emergency medicine. 

ADE-1 is an investigational drug and has not yet been approved by the FDA.


ADE-3 is a novel orally-active small molecule that is currently being assessed in preclinical studies as a treatment for muscle wasting, decreased physical strength and function, recovery from burn injuries, recovery from serious wounding trauma, sarcopenia, and osteoporosis.  It was designed to exhibit greater efficacy than current treatment options with a simultaneously reduced side effect profile.

ADE-3 is an investigational drug and has not yet been approved by the FDA.


Recent studies in military personnel have shown that beta-alanine supplementation effectively improves combat-specific performance, including marksmanship performance.  There is also evidence suggesting that optimally-dosed β-alanine supplementation may enhance cognitive function and promote resiliency during highly stressful situations.  

Further, supplementation with β-alanine may increase resiliency to acute heat stress, and may be protective against traumatic brain injury due to mild blast wave exposure — likely via its ability to moderate the inflammatory response, while increasing HSP70 and neurotrophins expression.

Beta-alanine, however, is complicated to properly administer.  Its half-life is short, and high doses frequently cause paresthesia, so optimal dosing regimens call for the administration of six or more doses per day.  This is rarely feasible for athletes, and is never feasible for military personnel.  

IBA6 is a beta-alanine derivative where six beta-alanine molecules are bonded to myo-inositol.  Some of these bonds are separated via hydrolysis in the gastrointestinal tract.  Subsequent exposure to esterases in plasma, and interactions with proteins that have esterase activity such as serum albumin, ensures the complete separation of the conjugate molecule.  Ultimately beta-alanine is steadily released over a period of 2-48 hours following a single dose of IBA6.

IBA6 was designed to be substantially more effective than beta-alanine at improving military performance, for various factors which include more convenient dosing and an improved pharmacokinetic profile, inositol’s augmentation of the biological effects of beta-alanine, and the fact that inositol itself is apparently effective at improving cognitive function and reducing anxiety in stressful situations.

Though designed for military use, IBA6 is of considerable interest to athletes.  Non-military applications have been licensed to the IBA6 company at


Combat drugs



Decipher 5d6924e8119b957f8d392aea8f7226b5